Jade Biosciences (JBIO) vs Seaport Therapeutics (SPTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Seaport Therapeutics is the larger company by market cap ($958.7 million vs $899.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JBIO | SPTX |
|---|---|---|
| Share price | $14.15 | $17.91 |
| Market cap | $899.90M | $958.73M |
| 1-day change | +2.76% | -0.11% |
| YTD return | -8.30% | — |
| 1-year return | +55.84% | — |
| 5-year return | -97.14% | — |
| EPS (TTM) | $-1.92 | $-5.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.00 | $28.38 |
| 52-week low | $8.36 | $14.85 |
| Distance from 52-week high | -49.46% | -36.89% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +254.28% | +113.79% |
| Average volume | 904.61K | 182.45K |
| Shares outstanding | 63.60M | 53.53M |
| Employees | 55 | 58 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Jade Biosciences
JBIO stock →Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Seaport Therapeutics
SPTX stock →Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
JBIO vs SPTX FAQ
Which is bigger, Jade Biosciences or Seaport Therapeutics?
Seaport Therapeutics (SPTX) is larger, with a market capitalization of $958.73M compared with $899.90M for Jade Biosciences (JBIO).
Are Jade Biosciences and Seaport Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.